More than 80% of oncologists frequently see mental health distress in their patients with cancer, and more than 90% say it has a significant impact on their health outcomes.
DUBLIN, Ohio, December 9, 2021 — More than 80% of oncologists frequently see mental health distress in their patients with cancer, and more than 90% say it has a significant impact on their health outcomes. These findings were released today in the latest edition of Oncology Insights, a report published by Cardinal Health Specialty Solutions based on surveys with more than 240 US oncologists.
Anxiety disorders and depression were cited by more than 80% of oncologists as the types of mental health distress seen most frequently in their patients, but personality and addiction disorders were also mentioned. Despite the high prevalence of mental health concerns, only a third of the surveyed oncologists said they frequently refer patients for mental health treatment and nearly half say there are not adequate resources available to support the mental health needs of cancer patients.
"Recent research indicates that mental health generally has declined since the start of the COVID-19 pandemic. This is particularly concerning for patients with cancer who are already at an increased risk for mental health distress," said Heidi Hunter, president of Cardinal Health Specialty Solutions. "Our latest oncology survey shines a light on this issue and provides insights on additional education and resources that could help oncologists to provide much-needed support to patients."
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Targeting Progression: Amivantamab’s Role in NSCLC After Osimertinib
October 24th 2024Amivantamab's role in non–small cell lung cancer (NSCLC) has been a highlight of the lung cancer space this year, with the 2 most recent approvals based on data from the MARIPOSA and MARIPOSA-2 trials.
Read More
Sarcoma Care: Biomarker Advancements Shape the Future
October 24th 2024At the regional Institute for Value-Based Medicine® event in Boston, Vinayak Venkataraman, MD, medical oncologist at Dana-Farber Cancer Institute and Harvard Medical School, was a panelist for the discussion, “Recent Advancements in Identifying Predictive Biomarkers for Sarcomas."
Read More